Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Mark L. Zangardi, Laura M. Spring, Aiko Nagayama, Aditya Bardia

Research output: Contribution to journalArticle

Abstract

Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered: We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion: Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3 rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.

Original languageEnglish
Pages (from-to)107-112
Number of pages6
JournalExpert Opinion on Investigational Drugs
Volume28
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Posters
Therapeutics
Clinical Trials, Phase I
Cytotoxins
Expert Testimony
United States Food and Drug Administration
Drug Delivery Systems
Pharmacokinetics
sacituzumab govitecan
Breast Neoplasms
Safety
Drug Therapy
Antibodies

Keywords

  • Antibody–drug conjugate
  • IMMU-132
  • metastatic breast cancer
  • sacituzumab govitecan
  • TNBC
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sacituzumab for the treatment of triple-negative breast cancer : the poster child of future therapy? / Zangardi, Mark L.; Spring, Laura M.; Nagayama, Aiko; Bardia, Aditya.

In: Expert Opinion on Investigational Drugs, Vol. 28, No. 2, 01.02.2019, p. 107-112.

Research output: Contribution to journalArticle

@article{8626c6f0312741958e98a57211fc9dc6,
title = "Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?",
abstract = "Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered: We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion: Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3 rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.",
keywords = "Antibody–drug conjugate, IMMU-132, metastatic breast cancer, sacituzumab govitecan, TNBC, triple-negative breast cancer",
author = "Zangardi, {Mark L.} and Spring, {Laura M.} and Aiko Nagayama and Aditya Bardia",
year = "2019",
month = "2",
day = "1",
doi = "10.1080/13543784.2019.1555239",
language = "English",
volume = "28",
pages = "107--112",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Sacituzumab for the treatment of triple-negative breast cancer

T2 - the poster child of future therapy?

AU - Zangardi, Mark L.

AU - Spring, Laura M.

AU - Nagayama, Aiko

AU - Bardia, Aditya

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered: We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion: Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3 rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.

AB - Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that disproportionately impacts younger women and is associated with a poor prognosis. Systemic treatment options for metastatic TNBC (mTNBC) are limited to cytotoxic chemotherapy agents with low response rates. This encouraged the clinical development of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate targeting Trop-2, a potential target in epithelial cancer such as TNBC. Areas covered: We summarize the key features, pharmacokinetics, and the safety and efficacy data of sacituzumab govitecan. We also discuss the future directions of this novel therapeutic agent for mTNBC. Expert opinion: Based on the efficacy and tolerability observed in the phase 1/2 clinical trial, sacituzumab govitecan was granted breakthrough therapy designation by the Food and Drug Administration as ≥3 rd line therapy for mTNBC. Novel treatment modalities for the management of mTNBC are necessary to improve the care of this aggressive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy and tolerability.

KW - Antibody–drug conjugate

KW - IMMU-132

KW - metastatic breast cancer

KW - sacituzumab govitecan

KW - TNBC

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85058695280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058695280&partnerID=8YFLogxK

U2 - 10.1080/13543784.2019.1555239

DO - 10.1080/13543784.2019.1555239

M3 - Article

C2 - 30507322

AN - SCOPUS:85058695280

VL - 28

SP - 107

EP - 112

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 2

ER -